Derar Jaradat1, Georgios Bagias1, Thomas Lorf2, Yaman Tokat3, Aiman Obed4, Arzu Oezcelik1. 1. Department of General, Visceral and Transplantation Surgery, University Hospital of Essen, Essen, Germany. 2. Department of Surgery, University of Göttingen, Göttingen, Germany. 3. Department of General and Transplantation Surgery, Florence Nightingale Hospital, University Hospital of Istanbul Bilim University, Istanbul, Turkey. 4. Department of Hepatobiliary and Organ Transplant Surgery, Hospital Jordan, Amman, Jordan.
Abstract
INTRODUCTION: Combined hepatocellular-cholangiocarcinoma is rare and comprises features of hepatocellular carcinoma and cholangiocarcinoma. The treatment of choice has not yet been defined. The aim of the study was to analyze outcomes of patients with combined hepatocellular-cholangiocarcinoma, who underwent liver transplantation. MATERIAL AND METHODS: All patients with combined hepatocellular-cholangiocarcinoma, who underwent liver transplantation, from January 2001 to August 2018 were identified. Pre-, intra- and postoperative data were retrospectively assessed. A univariate analysis was performed to identify prognostic factors. RESULTS: A total number of 19 patients were included to this study. Perioperative death was seen in two patients (10.5%). Recurrent disease was reported in 11 patients (64.7%) within the median time of 4 months. One and three years survival rates were 57.1% (CI 0.301-1) and 38.1% (CI 0.137-1). Factors associated mortality were tumor size >3 cm, presence of lymphatic invasion, and prolonged ICU stay. Patients with mixed HCC-CC lesions have significantly better survival compared to patients with separate lesions of HCC and CCC in one liver (p = .025). CONCLUSION: Although overall survival rates are clearly decreased compared to HCC patients, liver transplantation should be taken under consideration for selected patients with early stage and real mixed HCC-CC, who are likely to benefit from liver transplantation.
INTRODUCTION: Combined hepatocellular-cholangiocarcinoma is rare and comprises features of hepatocellular carcinoma and cholangiocarcinoma. The treatment of choice has not yet been defined. The aim of the study was to analyze outcomes of patients with combined hepatocellular-cholangiocarcinoma, who underwent liver transplantation. MATERIAL AND METHODS: All patients with combined hepatocellular-cholangiocarcinoma, who underwent liver transplantation, from January 2001 to August 2018 were identified. Pre-, intra- and postoperative data were retrospectively assessed. A univariate analysis was performed to identify prognostic factors. RESULTS: A total number of 19 patients were included to this study. Perioperative death was seen in two patients (10.5%). Recurrent disease was reported in 11 patients (64.7%) within the median time of 4 months. One and three years survival rates were 57.1% (CI 0.301-1) and 38.1% (CI 0.137-1). Factors associated mortality were tumor size >3 cm, presence of lymphatic invasion, and prolonged ICU stay. Patients with mixed HCC-CC lesions have significantly better survival compared to patients with separate lesions of HCC and CCC in one liver (p = .025). CONCLUSION: Although overall survival rates are clearly decreased compared to HCC patients, liver transplantation should be taken under consideration for selected patients with early stage and real mixed HCC-CC, who are likely to benefit from liver transplantation.
Authors: Safak Gül-Klein; Paulina Schmitz; Wenzel Schöning; Robert Öllinger; Georg Lurje; Sven Jonas; Deniz Uluk; Uwe Pelzer; Frank Tacke; Moritz Schmelzle; Johann Pratschke; Ramin Raul Ossami Saidy; Dennis Eurich Journal: Cancers (Basel) Date: 2022-06-11 Impact factor: 6.575
Authors: Ajacio Bandeira de Mello Brandão; Santiago Rodriguez; Alfeu de Medeiros Fleck; Claudio Augusto Marroni; Mário B Wagner; Alex Hörbe; Matheus V Fernandes; Carlos Ts Cerski; Gabriela Perdomo Coral Journal: World J Clin Oncol Date: 2022-08-24